Veru announces positive top-line interim data from phase 2 clinical trial of zuclomiphene

Veru announces positive top-line interim data from phase 2 clinical trial of zuclomiphene to treat hot flashes in men with prostate cancer on androgen deprivation therapy.veru inc - plans to advance zuclomiphene into pivotal phase 3 clinical trial in first half of 2020.veru - topline interim results demonstrate statistically significant fall in moderate to severe hot flashes from baseline was observed in 50mg group.veru inc - 10mg treatment group, as expected, did not show a statistically significant reduction in hot flashes from baseline.veru inc - zuclomiphene appears to be well tolerated.veru - there have been no reports of drug related serious adverse events nor drug related severe adverse events from zuclomiphene.
VERU Ratings Summary
VERU Quant Ranking